ALX Oncology Holdings Inc. Common Stock

ALXONASDAQUSD
1.98 USD
0.02 (1.00%)AT CLOSE (11:59 AM EDT)
1.98
0.01 (0.25%)
POST MARKET (AS OF 04:35 PM EDT)
Post Market
AS OF 04:35 PM EDT
1.98
0.01 (0.25%)
🔴Market: CLOSED

ALX Oncology Holdings Inc. Common Stock (ALXO) trades at $1.97 per share. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics suggest ALXO is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Aug 26, 2026.

Open?$1.98
High?$2.01
Low?$1.95
Prev. Close?$2.00
Volume?385.1K
Avg. Volume?922.7K
VWAP?$1.98
Rel. Volume?0.42x
Bid / Ask
Bid?$1.94 × 100
Ask?$2.08 × 100
Spread?$0.14
Midpoint?$2.01
Valuation & Ratios
Market Cap?273.8M
Shares Out?138.3M
Float?88.9M
Float %?66.0%
P/E Ratio?N/A
P/B Ratio?2.01
EPS?-$0.58
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Employees
48
Market Cap
276.6M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2020-07-17
Address
323 ALLERTON AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-466-7125
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Neutral(0/3)
Medium-Term (Wave)? Bearish(-1/3)
Short-Term (Ripple)? Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
1
Momentum?
65
Short Sent.?
60
Piotroski F-Score?0/9Weak
Altman Z-Score?-0.60Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?8.57%Elevated
Short Interest?7.6M
Days to Cover?4.8
Free Float88.9M
Avg Daily Volume1.6M
Settlement Date2026-08-14
Financial Health
Current Ratio?9.71Strong
Quick Ratio?9.71Strong
Cash Ratio?1.54Strong
Debt/Equity?0.07Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A
P/B?
Peers
100
S&P
74
2.01CHEAP
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
S&P
97
-3.2CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
3
-59.4%WEAK
ROA?
S&P
3
-50.3%WEAK
Cash Flow & Enterprise
FCF?$-70950000
Enterprise Value?$260.8M
Fundamentals ratios updated end of day